Casdin Capital’s iShares Biotechnology ETF IBB Stock Holding History

Casdin Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-60,000	Closed	-$5.79M	–	30
2018 Q4	$5.79M	Buy	+60,000	New	+$6.37M	0.99%	27
2018 Q2	–	Sell	-95,000	Closed	-$10.1M	–	37
2018 Q1	$10.1M	Buy	+95,000	New	+$10.5M	1.78%	21
2016 Q4	–	Sell	-15,000	Closed	-$1.45M	–	27
2016 Q3	$1.45M	Buy	+15,000	New	+$1.43M	1.17%	22

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Casdin Capital's IBB Position: Q1 2019 in Review

Casdin Capital sold out of iShares Biotechnology ETF (IBB) in Q1 2019, closing a stake of 60,000 shares — an estimated $5.79M sold.

Casdin Capital first reported a position in IBB in Q3 2016 and held it in 3 quarters. The position peaked at $10.1M in Q1 2018. 670 funds tracked by Wall St. Rank hold IBB as of Q1 2019.

Casdin Capital reported no remaining iShares Biotechnology ETF position as of Q1 2019 after selling out during the quarter.
Casdin Capital sold 60,000 iShares Biotechnology ETF shares in Q1 2019, an estimated $5.79M.
Casdin Capital first reported a position in iShares Biotechnology ETF in Q3 2016 and held it in 3 quarters.
Casdin Capital's iShares Biotechnology ETF position peaked at $10.1M in Q1 2018.
670 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2019.

Based on Casdin Capital's 13F filing for Q1 2019, filed 15 May 2019.